Italy has solidified its position as one of Europe’s foremost pharmaceutical producers, marked by exceptional growth and an expanding global presence. In 2023, the pharmaceutical sector in Italy achieved a production value exceeding €52 billion. This growth is mirrored by a rise in overall employment within the sector, which now supports around 70,000 workers. The financial performance of Italy’s pharmaceuticals industry is equally notable. In 2022, net revenues soared to nearly €35.5 billion, which also includes the thriving cosmetic industry. This revenue contributed an added value of around €11.9 billion to Italy’s economy in 2023. Italy’s pharmaceuticals industry remains mostly export oriented. Over the past decade, the sector’s dependence on international markets has increased, with exports becoming a vital component of its success. In 2023, Italy’s pharmaceutical exports reached €49 billion; three times the figure reported in 2011. Major export destinations include Belgium, the United States, and Germany. Despite a high export volume, Italy remains reliant on pharmaceutical imports, which amounted to over €38.4 billion in 2023. Research and development (R&D) are pivotal to maintaining Italy’s competitive edge in the global pharmaceutical landscape. In 2023, the sector invested €2 billion in R&D, with nearly 6,000 employees engaged in advancing pharmaceutical innovation. These investments are crucial for sustaining growth, fostering new drug development, and ensuring Italy's leadership in medical advancements. Among the prominent players in the Italian pharmaceutical sector are Menarini and Chiesi. Menarini, achieving revenues exceeding €4 billion in 2022, has seen remarkable success, with over 75% of its revenues now generated outside Italy. The company’s international expansion, which began in the 1960s, has firmly established it as a global player. Chiesi, another significant Italian pharmaceutical company, reported strong revenues of €2.7 billion in 2022. Both companies exemplify Italy’s dynamic and internationally competitive pharmaceutical sector.